Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
270 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Osteoarthritis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides an overview of the Osteoarthritis (Immunology) pipeline landscape. Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Osteoarthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 21, 14, 46 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 5 molecules, respectively. Osteoarthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Immunology). - The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Osteoarthritis (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Osteoarthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Osteoarthritis - Overview 11 Osteoarthritis - Therapeutics Development 12 Pipeline Overview 12 Pipeline by Companies 13 Pipeline by Universities/Institutes 19 Products under Development by Companies 20 Products under Development by Universities/Institutes 26 Osteoarthritis - Therapeutics Assessment 27 Assessment by Target 27 Assessment by Mechanism of Action 30 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Osteoarthritis - Companies Involved in Therapeutics Development 37 A. Menarini Industrie Farmaceutiche Riunite Srl 37 AbbVie Inc 37 Abiogen Pharma SpA 38 Ablynx NV 38 Achelios Therapeutics Inc 39 Addex Therapeutics Ltd 39 Amgen Inc 40 Amura Holdings Ltd 40 Arcarios BV 41 Asahi Kasei Pharma Corp 41 Asklepios BioPharmaceutical Inc 42 Astellas Pharma Inc 42 Biopharm GmbH 43 Bone Therapeutics SA 43 Can-Fite BioPharma Ltd 44 Cardax Inc 44 Cellular Biomedicine Group Inc 45 Cipla Ltd 45 Corestem Inc 46 Dong-A Socio Holdings Co Ltd 46 Evgen Pharma Plc 47 F. Hoffmann-La Roche Ltd 47 Galapagos NV 48 Gemphire Therapeutics Inc 48 GeneFrontier Corp 49 Genequine Biotherapeutics GmbH 49 GlaxoSmithKline Plc 50 HSRx Group 50 InKemia IUCT Group SA 51 International Stem Cell Corp 51 Jeil Pharmaceutical Co Ltd 52 Jenrin Discovery Inc 52 K-Stemcell Co Ltd 53 Kang Stem Biotech Co Ltd 53 Levolta Pharmaceuticals Inc 54 LG Chem, Ltd. 54 Marina Biotech Inc 55 Medivir AB 55 Merck KGaA 56 Mesoblast Ltd 56 Mor Research Application Ltd 57 NicOx SA 57 Nordic Bioscience A/S 58 Novartis AG 58 NovelMed Therapeutics Inc 59 Omeros Corp 59 Ono Pharmaceutical Co Ltd 60 OrthoCyte Corp 60 Osteologix Holdings Plc 61 Pfizer Inc 61 Pharmalink AB 62 Philogen SpA 62 PhytoHealth Corp 63 PLx Pharma Inc 63 ProteoThera Inc 64 Regeneus Ltd 64 Regulaxis SAS 65 Rottapharm Biotech Srl 65 Samumed LLC 66 Seikagaku Corp 66 Stelis Biopharma Pvt Ltd 67 Takeda Pharmaceutical Company Ltd 67 TissueGene Inc 68 Yooyoung Pharmaceutical Co Ltd 68 Yuhan Corp 69 Yungjin Pharm Co Ltd 69 Zimmer Biomet Holdings Inc 70 Osteoarthritis - Drug Profiles 71 (clodronate disodium + hyaluronic acid) - Drug Profile 71 (methylprednisolone + zoledronic acid) - Drug Profile 72 4-P004 - Drug Profile 74 ABT-981 - Drug Profile 75 ALLO-ASC - Drug Profile 76 AlloJoin - Drug Profile 78 AM-3701 - Drug Profile 79 AM-3876 - Drug Profile 80 Anatabine - Drug Profile 81 Antibody for Osteoarthritis - Drug Profile 84 Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile 85 apocynin + paeonol - Drug Profile 86 ARC-118 - Drug Profile 87 AS-001 - Drug Profile 88 BNP-OA - Drug Profile 89 CDX-085 - Drug Profile 90 celecoxib - Drug Profile 93 Cell Therapy for Osteoarthritis - Drug Profile 94 Chondrostem - Drug Profile 95 clodronate disodium - Drug Profile 96 CMX-020 - Drug Profile 97 CR-8357 - Drug Profile 98 CRB-0017 - Drug Profile 99 CS-30MS02 - Drug Profile 100 DA-5202 - Drug Profile 101 denosumab - Drug Profile 102 DIS-BIO-EPS - Drug Profile 112 DNX-314 - Drug Profile 113 Drug for Bone Diseases and Osteoarthritis - Drug Profile 114 Drug for Osteoarthritis - Drug Profile 115 Drug for Osteoarthritis - Drug Profile 116 Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 117 Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile 118 fasitibant chloride - Drug Profile 119 gemcabene calcium - Drug Profile 120 GFC-301 - Drug Profile 124 GLPG-1972 - Drug Profile 125 GQ-203 - Drug Profile 126 GQ-303 - Drug Profile 127 GSK-2394002 - Drug Profile 128 JD-4000 Series - Drug Profile 129 Jointstem - Drug Profile 130 JTA-004 - Drug Profile 132 Kartogenin - Drug Profile 133 KBP-056 - Drug Profile 134 ketoprofen - Drug Profile 135 LEVI-04 - Drug Profile 137 LH-021 - Drug Profile 138 LNA-043 - Drug Profile 139 MIV-711 - Drug Profile 140 Monoclonal Antibodies for Oncology, Inflammation and Osteoarthritis - Drug Profile 143 Monoclonal Antibody Conjugates for Osteoarthritis - Drug Profile 144 Monoclonal Antibody for Osteoarthritis - Drug Profile 145 MPC-75IA - Drug Profile 146 naproxcinod - Drug Profile 147 NBS-101 - Drug Profile 150 NStride APS - Drug Profile 152 ONO-4474 - Drug Profile 153 OTXCP-03 - Drug Profile 154 OTXCP-07 - Drug Profile 155 PF-152 - Drug Profile 156 PHDC-02 - Drug Profile 157 piclidenoson - Drug Profile 158 PL-1100 - Drug Profile 167 PN-6047 - Drug Profile 168 PRO-1 - Drug Profile 169 Progenza - Drug Profile 170 Protein for Osteoarthritis and Asthma - Drug Profile 172 Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile 173 PRX-167700 - Drug Profile 174 Recombinant Protein for Osteoarthritis - Drug Profile 176 Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 177 Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 179 Recombinant Protein to Agonize IL-4 and IL-10 Receptors for Osteoarthritis and CNS - Drug Profile 180 Reg-O3 - Drug Profile 181 ReJoin - Drug Profile 182 salmon calcitonin - Drug Profile 186 SBL-005 - Drug Profile 188 SFX-01 - Drug Profile 189 SI-613 - Drug Profile 192 SM-04690 - Drug Profile 193 Small Molecule for Degenerative Arthritis - Drug Profile 196 Small Molecule for Osteoarthritis - Drug Profile 197 Small Molecule for Osteoarthritis - Drug Profile 198 Small Molecule for Osteoarthritis - Drug Profile 199 Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile 200 Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 201 Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile 202 Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile 203 Small Molecules for Osteoarthritis - Drug Profile 204 Small Molecules for Osteoarthritis - Drug Profile 205 Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis - Drug Profile 206 Small Molecules to Inhibit iNOS for Osteoarthritis - Drug Profile 207 Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile 208 sprifermin - Drug Profile 209 Stem Cell Therapy for Articular Cartilage Lesions and Osteoarthritis - Drug Profile 211 Stem Cell Therapy for Autoimmune Diseases - Drug Profile 212 Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 214 Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile 215 Stem Cell Therapy for Osteoarthritis and Rheumatoid Arthritis - Drug Profile 216 Stem Cell Therapy for Osteoarthritis, Atherosclerosis and Arteriosclerosis Obliterans - Drug Profile 217 Stempeucel - Drug Profile 218 tonogenchoncel-L - Drug Profile 221 TPX-100 - Drug Profile 224 TRBN-0224 - Drug Profile 226 UGP-302 - Drug Profile 228 VA-694 - Drug Profile 230 X-0002 - Drug Profile 231 XT-101 - Drug Profile 233 XT-150 - Drug Profile 234 YH-14619 - Drug Profile 235 YRA-1909 - Drug Profile 236 YY-1201 - Drug Profile 237 YYD-302 - Drug Profile 238 Osteoarthritis - Dormant Projects 239 Osteoarthritis - Discontinued Products 246 Osteoarthritis - Product Development Milestones 248 Featured News & Press Releases 248 Appendix 261 Methodology 261 Coverage 261 Secondary Research 261 Primary Research 261 Expert Panel Validation 261 Contact Us 261 Disclaimer 262
List of Tables
Number of Products under Development for Osteoarthritis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017 Osteoarthritis - Pipeline by AbbVie Inc, H1 2017 Osteoarthritis - Pipeline by Abiogen Pharma SpA, H1 2017 Osteoarthritis - Pipeline by Ablynx NV, H1 2017 Osteoarthritis - Pipeline by Achelios Therapeutics Inc, H1 2017 Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H1 2017 Osteoarthritis - Pipeline by Amgen Inc, H1 2017 Osteoarthritis - Pipeline by Amura Holdings Ltd, H1 2017 Osteoarthritis - Pipeline by Arcarios BV, H1 2017 Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp, H1 2017 Osteoarthritis - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017 Osteoarthritis - Pipeline by Astellas Pharma Inc, H1 2017 Osteoarthritis - Pipeline by Biopharm GmbH, H1 2017 Osteoarthritis - Pipeline by Bone Therapeutics SA, H1 2017 Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd, H1 2017 Osteoarthritis - Pipeline by Cardax Inc, H1 2017 Osteoarthritis - Pipeline by Cellular Biomedicine Group Inc, H1 2017 Osteoarthritis - Pipeline by Cipla Ltd, H1 2017 Osteoarthritis - Pipeline by Corestem Inc, H1 2017 Osteoarthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017 Osteoarthritis - Pipeline by Evgen Pharma Plc, H1 2017 Osteoarthritis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Osteoarthritis - Pipeline by Galapagos NV, H1 2017 Osteoarthritis - Pipeline by Gemphire Therapeutics Inc, H1 2017 Osteoarthritis - Pipeline by GeneFrontier Corp, H1 2017 Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H1 2017 Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H1 2017 Osteoarthritis - Pipeline by HSRx Group, H1 2017 Osteoarthritis - Pipeline by InKemia IUCT Group SA, H1 2017 Osteoarthritis - Pipeline by International Stem Cell Corp, H1 2017 Osteoarthritis - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017 Osteoarthritis - Pipeline by Jenrin Discovery Inc, H1 2017 Osteoarthritis - Pipeline by K-Stemcell Co Ltd, H1 2017 Osteoarthritis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017 Osteoarthritis - Pipeline by Levolta Pharmaceuticals Inc, H1 2017 Osteoarthritis - Pipeline by LG Chem, Ltd., H1 2017 Osteoarthritis - Pipeline by Marina Biotech Inc, H1 2017 Osteoarthritis - Pipeline by Medivir AB, H1 2017 Osteoarthritis - Pipeline by Merck KGaA, H1 2017 Osteoarthritis - Pipeline by Mesoblast Ltd, H1 2017 Osteoarthritis - Pipeline by Mor Research Application Ltd, H1 2017 Osteoarthritis - Pipeline by NicOx SA, H1 2017 Osteoarthritis - Pipeline by Nordic Bioscience A/S, H1 2017 Osteoarthritis - Pipeline by Novartis AG, H1 2017 Osteoarthritis - Pipeline by NovelMed Therapeutics Inc, H1 2017 Osteoarthritis - Pipeline by Omeros Corp, H1 2017 Osteoarthritis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Osteoarthritis - Pipeline by OrthoCyte Corp, H1 2017 Osteoarthritis - Pipeline by Osteologix Holdings Plc, H1 2017 Osteoarthritis - Pipeline by Pfizer Inc, H1 2017 Osteoarthritis - Pipeline by Pharmalink AB, H1 2017 Osteoarthritis - Pipeline by Philogen SpA, H1 2017 Osteoarthritis - Pipeline by PhytoHealth Corp, H1 2017 Osteoarthritis - Pipeline by PLx Pharma Inc, H1 2017 Osteoarthritis - Pipeline by ProteoThera Inc, H1 2017 Osteoarthritis - Pipeline by Regeneus Ltd, H1 2017 Osteoarthritis - Pipeline by Regulaxis SAS, H1 2017 Osteoarthritis - Pipeline by Rottapharm Biotech Srl, H1 2017 Osteoarthritis - Pipeline by Samumed LLC, H1 2017 Osteoarthritis - Pipeline by Seikagaku Corp, H1 2017 Osteoarthritis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2017 Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Osteoarthritis - Pipeline by TissueGene Inc, H1 2017 Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co Ltd, H1 2017 Osteoarthritis - Pipeline by Yuhan Corp, H1 2017 Osteoarthritis - Pipeline by Yungjin Pharm Co Ltd, H1 2017 Osteoarthritis - Pipeline by Zimmer Biomet Holdings Inc, H1 2017 Osteoarthritis - Dormant Projects, H1 2017 Osteoarthritis - Dormant Projects, H1 2017 (Contd..1), H1 2017 Osteoarthritis - Dormant Projects, H1 2017 (Contd..2), H1 2017 Osteoarthritis - Dormant Projects, H1 2017 (Contd..3), H1 2017 Osteoarthritis - Dormant Projects, H1 2017 (Contd..4), H1 2017 Osteoarthritis - Dormant Projects, H1 2017 (Contd..5), H1 2017 Osteoarthritis - Discontinued Products, H1 2017 Osteoarthritis - Discontinued Products, H1 2017 (Contd..1), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
